Study S001468

A Relative Bioavailability Study to Compare the Pharmacokinetics of LY3437943 Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants

ClinicalTrials.gov record

Registration

Registration: NCT06003465
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 57
Start: 2023-08-29
Primary completion: 2024-02-08
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: DRUG:LY3437943; DEVICE:Test; DEVICE:Reference
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J1I-MC-GZBX

Registered primary outcomes

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943 [Predose up to 43 days postdose]
PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of LY3437943 [Predose up to 43 days postdose]
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943 [Predose up to 43 days postdose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.